ViiV Healthcare’s phase 3 study of dolutegravir plus lamivudine meets primary endpoint

This article was originally published here

The TANGO study was conducted to assess whether adults living with HIV-1 who had maintained viral suppression for at least six months on a tenofovir alafenamide fumarate (TAF)-containing

The post ViiV Healthcare’s phase 3 study of dolutegravir plus lamivudine meets primary endpoint appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply